|H M R||Endogenous||165, 70||Rabbit|
For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody datasheet or product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
posted June 2005
revised November 2013
Reprobing of an existing membrane is a convenient means to immunoblot for multiple proteins independently when only a limited amount of sample is available. It should be noted that for the best possible results a fresh blot is always recommended. Reprobing can be a valuable method but with each reprobing of a blot there is potential for increased background signal. Additionally, it is recommended that you verify the removal of the first antibody complex prior to reprobing so that signal attributed to binding of the new antibody is not leftover signal from the first immunoblotting experiment. This can be done by re-exposing the blot to ECL reagents and making sure there is no signal prior to adding the next primary antibody.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalently purified water.
posted June 2005
revised June 2016
Protocol Id: 263
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
NALP1 Antibody detects endogenous levels of total NALP1 protein. This antibody also detects a 70 kDa protein that correlates with a predicted short form (NALP1s) that lacks the leucine repeat region (7).
Human, Mouse, Rat
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide that corresponds to a region surrounding Gly1081 of human NALP1 protein. Antibodies were purified by peptide affinity chromatography.
NALP1 (DEFCAP/NAC/CARD7) is an NLR (Nod-like receptor) family member that has been implicated in the regulation of apoptosis and inflammatory responses (1-5). Structurally, NALP contains an amino-terminal PYRIN domain, followed by a nucleotide-binding site (NBS), a leucine rich repeat region (LRR), and a carboxy-terminal CARD domain. NALP1 and interacts strongly with caspase-2 and weakly with caspase-9, and induces apoptosis when overexpressed (3). Similar to a related Ced-4 family member Apaf-1, it was also shown to be involved in cytochrome c-dependent caspase activation (2). It has also been shown to be part of the "inflammasome" comprised of caspase-1, caspase-5, and Pycard/ASC, which is critical in the processing of pro-inflammatory cytokines like IL-1β (6). Two major isoforms were identified for NALP1, which differ in a 44 amino acid region within the LRR (3). In addition, like NALP3, a short NALP1 isoform lacking the LRR (NALP1s) likely exists (7). Polymorphisms in NALP1 have been associated with autoimmune disease (8) and susceptibility to toxins (9).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|4990S||100 µl (10 western blots)||$255.00.0|